Background Papillary thyroid cancer (PTC) is the most common endocrine malignancy
worldwide. The treatment of PTC has attracted extensive attention and discussion from the …

Abstract Background In 2010, the Japanese Society of Thyroid Surgeons (JSTS) and
Japanese Association of Endocrine Surgeons (JAES) established new guidelines entitled …

Context: There is uncertainty over the dose of 131I required for thyroid remnant ablation.
Most previous studies have been inadequately powered to establish the best fixed dose of …

First introduced in 1946, radioactive iodine (I-131) produces short-range beta radiation with
a half-life of 8 days. The physical properties of I-131 combined with the high degree of …

Purpose In the ESTIMABL phase III trial, the thyroid ablation rate was equivalent for the two
thyroid-stimulating hormone (TSH) stimulation methods (thyroid hormone withdrawal [THW] …

Management recommendations for differentiated thyroid cancer are evolving. Total
thyroidectomy is the backbone of curative-intent therapy, with radioiodine ablation (RAI) of …

In the years since the publication of the Third Series AFIP Fascicles on the thyroid and
parathyroid glands, awareness of the remarkable morphologic diversity of thyroid carcinoma …

This systematic review provides a summary of all studies published between 2000 and 2019
using a health-related quality of life (HRQOL) patient-completed questionnaire to report …

Thyroid cancer is the most common endocrine cancer in the United States. The primary
treatment of thyroid cancer is partial or complete thyroidectomy in patients in whom the …

The most frequent thyroid cancer is Differentiated Thyroid Cancer (DTC) representing more
than 95% of cases. A suitable choice for the treatment of DTC is the systemic administration …